PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Original from: PathAI

PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation’s top cancer hospitals and a leader in cancer research, today announced a multi-year strategic collaboration to deploy PathAI’s digital pathology platform, AISight® Dx, across Moffitt’s pathology programs to transform cancer detection and innovation. 

AISight® Dx, is PathAI’s cloud-native digital pathology image management system designed to support both laboratory workflow and translational research use cases. It combines enterprise-scale slide management, viewing, and collaboration with seamless AI integration, driving scalable pathology operational efficiencies and enhanced speed and accuracy. The partnership also establishes a framework for joint research programs, collation of real-world multimodal data, initiatives to support clinical trials and biopharma collaborations, and the co-development of next-generation AI-based diagnostics to enhance precision medicine. 

“We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care,” said Andy Beck, MD, PhD, CEO and Co-Founder of PathAI. “By deploying AISight® Dx and building this strategic partnership, we’re equipping Moffitt’s pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.”

“This collaboration aligns perfectly with Moffitt’s mission to contribute to the prevention and cure of cancer through transformative care, cutting-edge science and innovation,” said Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center. “By deploying AISight® Dx into our pathology infrastructure, we’re taking a significant step forward in the integration of AI-driven technology into clinical oncology, enabling faster, more accurate pathologist review.

“Adopting cutting-edge digital pathology technologies is key to driving Moffitt’s vision for a true digital transformation, one that unlocks a wealth of pathology data and seamlessly integrates it with imaging and clinical insights to deliver truly personalized patient care,” said William Westra, MD, vice chair of Pathology at Moffitt Cancer Center. “By partnering with PathAI, we’re laying the groundwork for next-generation oncology research that will shape future AI-powered care models, while building on PathAI’s and Moffitt’s legacy of advancing cancer pathology, innovative therapies, and breakthrough diagnostics.”

Together, PathAI and Moffitt Cancer Center aim to redefine the role of digital pathology and AI in cancer care, setting a precedent for how cutting-edge technologies and clinical expertise can converge to drive meaningful improvements in pathology. 

Source: PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics